Microvesicles facilitate the differentiation of mesenchymal stem cells into pancreatic beta-like cells via miR-181a-5p/150-5p

MingMing Ning(University of Calgary), Haijia Yu(Second Affiliated Hospital of Jilin University), Kai Xu(Nanjing Normal University), Ying Ma(Nanjing Normal University), Shanshan Hua(Qingdao University), Dianliang Wang(Air Force General Hospital PLA), Yunpeng Liu(Shenyang Institute of Automation)
International Journal of Biological Macromolecules
November 2, 2023
10.1016/j.ijbiomac.2023.127719
Cited by 6

Related Papers

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
|Clinical Cancer Research|2018|551
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2022|417
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial
|The Lancet Oncology|2015|412